Compare JELD & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JELD | PEPG |
|---|---|---|
| Founded | 1960 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.7M | 179.4M |
| IPO Year | 2016 | 2022 |
| Metric | JELD | PEPG |
|---|---|---|
| Price | $1.41 | $2.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $1.93 | ★ $10.19 |
| AVG Volume (30 Days) | ★ 1.6M | 724.1K |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $1.31 |
| 52 Week High | $4.92 | $7.80 |
| Indicator | JELD | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 49.70 |
| Support Level | $1.31 | $1.60 |
| Resistance Level | $2.18 | $2.62 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 14.90 | 75.00 |
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.